臨床婦人科産科69巻1号

2015年01月発行

今月の臨床 ゲノム時代の婦人科がん診療を展望する─がんの個性に応じたpersonalizationへの道

【各論2】子宮体がん

5．子宮肉腫（平滑筋肉腫）の病態と分子標的治療─ゲノム解析に基づく新たな展開

著者： 吉田好雄¹

所属機関： ¹福井大学医学部産科婦人科

ページ範囲：P.96 - P.105

文献概要

●稀少性と，多様性のある腫瘍である．細胞代謝・細胞構造・シグナル伝達・細胞周期などに関する多くの遺伝子異常を有する．

●発生病態は依然不明である．しかし，一部の子宮平滑筋肉腫と平滑筋腫は共通の遺伝子異常を認める．

●血管新生阻害薬・ホルモン療法（アロマターゼ阻害薬）などの分子標的薬の有効性が検討されている．これらの治療効果予測バイオマーカーとして，分子イメージング診断法の開発が今後期待される．

参考文献

1） Helman LJ, et al : Mechanisms of sarcoma development. Nat Rev Cancer 3 : 685─694, 2003

2） Hernando E, et al : The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13 : 748─753, 2007

3） Xing D, et al : A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 69 : 8231─8235, 2009

4） Strizzi L, et al : Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol 211 : 36─44, 2007

5） Hayashi T, et al : Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 62 : 24─27, 2002

6） Cho YL, et al : Array comparative genomic hybridization analysis of uterine leiomyosarcoma. Gynecol Oncol 99 : 545─551, 2005

7） Nielsen TO, et al : Molecular characterisation of soft tissue tumours : a gene expression study. Lancet 359 : 1301─1307, 2002

8） Yang J, et al : Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett 275 : 1─8, 2009

9） Setsu N, et al : The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 118 : 1637─1648, 2012

10） Wong TF, et al : Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol 122 : 141─148, 2011

11） Dei Tos AP, et al : Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 148 : 1037─1045, 1996

12） Meza-Zepeda LA, et al : Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res 66 : 8984─8993, 2006

13） Brewer Savannah KJ, et al : Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res 18 : 4633─4645, 2012

14） Cordon-Cardo C, et al : Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54 : 794─799, 1994

15） Skubitz KM, et al : Differential gene expression in leiomyosarcoma. Cancer 98 : 1029─1038, 2003

16） Quade BJ, et al : Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 40 : 97─108, 2004

17） Matsumura N, et al : Oncogenic property of acrogranin in human uterine leiomyosarcoma : direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 12 : 1402─1411, 2006

18） Davidson B, et al : Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol 45 : 691─700, 2014

19） Amant F, et al : Clinical management of uterine sarcomas. Lancet Oncol 10 : 1188─1198, 2009

20） Rao UN, et al : Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 12 : 1001─1009, 1999

21） Kelley TW, et al : Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas : an immunohistochemical study. Appl Immunohistochem Mol Morphol 12 : 338─341, 2004

22） Mäkinen N, et al : MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334 : 252─255, 2011

23） Kämpjärvi K, et al : Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer 107 : 1761─1765, 2012

24） Pérot G, et al : MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7 : e40015, 2012

25） Schwetye KE, et al : MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 45 : 65─70, 2014

26） Zhang Q, et al : Molecular analyses of 6 different types of uterine smooth muscle tumors : emphasis in atypical leiomyoma. Cancer, 2014［Epub ahead of print］

27） Thanopoulou E, et al : Hormonal therapy in gynecological sarcomas. Expert Rev Anticancer Ther 12 : 885─894, 2012

28） O’Cearbhaill R, et al : Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 116 : 424─429, 2010

29） George S, et al : Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 120 : 738─743, 2014

30） Thanopoulou E, et al : Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res 4 : 5, 2014

31） Zhao Z, et al : 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors : correlation with immunohistochemical analysis. J Nucl Med 54 : 499─506, 2013

32） van der Graaf WT, et al : EORTC Soft Tissue and Bone Sarcoma Group ; PALETTE study group : Pazopanib for metastatic soft-tissue sarcoma（PALETTE） : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879─1886, 2012

33） Hensley ML, et al : Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma : a Gynecologic Oncology Group phase II study. Gynecol Oncol 115 : 460─465, 2009

34） Maki RG, et al : Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27 : 3133─3140, 2009

35） Verschraegen CF, et al : Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma : the Axtell regimen. Ann Oncol 23 : 785─790, 2012

36） D’Adamo DR, et al : Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 : 7135─7142, 2005

37） Demetri GD, et al : Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 31 : 2485─2492, 2013